Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Registers A Win For Older People RSV Vaccine – But Awaited Data Will Be Crucial

Prevention Rate Still Undisclosed

Executive Summary

GSK has declared success for its RSV vaccine and will begin regulatory talks immediately – but the final efficacy level, as yet unrevealed, could be decisive in a competitive market.

You may also be interested in...



RSV Vaccine May Be On Market In 2023, CDC’s ACIP Anticipates

Panel expects to review five respiratory syncytial virus vaccines and vote on one or two of them in June 2023 and others four months later. Sanofi presents results of three clinical trials of its monoclonal antibody nirsevimab, which is on track to be the second RSV prophylaxis for infants.

GSK Halts Enrollment In Maternal RSV Vaccine Trials As Setback Intensifies

The company has not revealed any details of the potential safety issue that led to the decision.

J&J Sets The Pace In Race To $10bn RSV Vaccine Market

Johnson & Johnson has impressed with its Phase II data but Pfizer and GSK have both already begun their Phase III studies.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC146532

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel